The Role of Breast Cancer Derived Prostaglandin E2 in the Elaboration of a Therapeutic Immune Response
Abstract
We postulated that the production of prostanoids, principally prostaglandin E2 (PGE2), by human breast cancers contributes to the lack of a significant immune response to breast cancer cells. We have conducted a series of experiments to show that human breast cancer cells commonly secrete soluble agents that directly inhibit T lymphocytes. Following up on our preliminary data, we demonstrated that one of the major inhibitory factors made by breast cancer cells is PGE2. Specifically, tumor conditioned media containing PGE2 is able to inhibit T cell proliferation.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 1999
- Accession Number
- ADA385254
Entities
People
- Stephen L. Eck
Organizations
- University of Pennsylvania